Table 1.
Competition binding (pKi) and activation (pEC50) by H2 relaxin analogs of RXFP1, and by INSL3 analogs of RXFP2, and molecular weight of peptides.
| Peptide | RXFP1 | RXFP2 | MW | |||
|---|---|---|---|---|---|---|
| pKi | pEC50 | pKi | pEC50 | Calculated | Observed | |
| Native H2 relaxin | 9.45 ± 0.14 | 10.71 ± 0.14 | ND | ND | 5961.23 | 5960.33 |
| Cy5.5-H2 relaxin | 7.79 ± 0.26 | 8.99 ± 0.23 | ND | ND | 6781.25 | 6780.81 |
| Cy5.5-H2:A(4-24)(F23A) | 7.63 ± 0.25 | 8.61 ± 0.06 | NA | NA | 6301.61 | 6301.68 |
| Native INSL3 | NA | NA | 9.09 ± 0.22 | 10.40 ± 0.07 | 6778.54 | 6279.46 |
| Cy5.5-INSL3 | NA | NA | 8.21 ± 0.28 | 9.01 ± 0.22 | 7100.38 | 7100.15 |